|

A Study to Test CRT-402 in Refractory Autoimmune Disease

RECRUITINGPhase 1/2Sponsored by Myeloid Therapeutics
Actively Recruiting
PhasePhase 1/2
SponsorMyeloid Therapeutics
Started2026-08-26
Est. completion2028-12-01
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Patients with refractory autoimmune diseases often have limited treatment options and ongoing disease activity despite standard therapies. CRT-402 is an in vivo Cluster of differentiation 19 (CD19)-targeted CAR-T cell therapy designed to deplete CD19-positive B cells and promote immune system reset. This study evaluates the safety, tolerability, preliminary efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) of CRT-402 in participants with active refractory systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age 18 years or older.
* Diagnosis of active, refractory systemic lupus erythematosus, systemic sclerosis, or idiopathic inflammatory myopathy meeting established classification criteria, with inadequate response or intolerance to standard therapy.
* Adequate renal, hepatic, cardiac, and pulmonary function per protocol-defined criteria.
* Participants of reproductive potential must agree to use protocol-specified contraception during the study and for a defined period after dosing.
* Females of childbearing potential must have a negative pregnancy test before treatment.
* Must be willing and able to attend study visits and follow all study requirements.

Exclusion Criteria:

* Clinical suitability for a less burdensome and/or approved therapeutic approach, as judged by the Investigator,
* Any medical condition or laboratory abnormality that, in the Investigator's judgment, would place the participant at unacceptable risk or confound interpretation of study data,
* Prior Cluster of differentiation 19 (CD19)-directed, cell, or gene therapy,
* History of bone marrow/ hematopoietic stem cell or solid organ transplantation,
* Active or inadequately treated infection, including Human immunodeficiency (HIV), hepatitis B or C, or tuberculosis,
* Pregnancy or lactation.

Conditions5

Autoimmune DiseasesLupusMyositisSystemic Lupus ErythematosusSystemic Scleroderma

Interventions1

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.